Omar Abdel-Rahman1, Mostafa Eltobgy2, Hani Oweira3,4,5, Anwar Giryes3, Aysun Tekbas5, Michael Decker6. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11566, Egypt. 2. Faculty of Medicine, Ain Shams University, Cairo, Egypt. 3. Oncology Department, Swiss Cancer Institute, Cham, Switzerland 3OncoCentrum Zurich, Gastrointestinal Tumor Center Zurich (GITZ), Zurich, Switzerland. 4. Surgical Center Zurich - Hirslanden Hospital Zurich, Zurich, Switzerland. 5. Surgery Department, University of Jena, Jena, Germany. 6. Oncology Department, Zentrum für Integrative Onkologie, 8001 Zurich, Switzerland.
Abstract
AIM: Immune-related musculoskeletal toxicities are uncommon but potentially serious adverse events; and they may accompany the use of immune checkpoint inhibitors (ICIs). The objective of this systematic review is to assess the patterns of these musculoskeletal toxicities. METHODS & RESULTS: PubMed database has been searched till May 2017. Clinical studies and case reports reporting the occurrence of immune-related musculoskeletal toxicities (other than arthralgia and myalgia) in cancer patients treated with ICIs were included. Eight trials with 2263 participants were included. Likewise, nine case reports reporting the outcomes of 12 patients were included. CONCLUSION: Immune-related arthritis and myositis occur uncommonly in cancer patients treated with ICIs. Further studies are required to better describe the pathogenesis as well as the time course of these events.
AIM: Immune-related musculoskeletal toxicities are uncommon but potentially serious adverse events; and they may accompany the use of immune checkpoint inhibitors (ICIs). The objective of this systematic review is to assess the patterns of these musculoskeletal toxicities. METHODS & RESULTS: PubMed database has been searched till May 2017. Clinical studies and case reports reporting the occurrence of immune-related musculoskeletal toxicities (other than arthralgia and myalgia) in cancerpatients treated with ICIs were included. Eight trials with 2263 participants were included. Likewise, nine case reports reporting the outcomes of 12 patients were included. CONCLUSION: Immune-related arthritis and myositis occur uncommonly in cancerpatients treated with ICIs. Further studies are required to better describe the pathogenesis as well as the time course of these events.
Authors: Kevin Tyan; Joanna Baginska; Martha Brainard; Anita Giobbie-Hurder; Mariano Severgnini; Michael Manos; Rizwan Haq; Elizabeth I Buchbinder; Patrick A Ott; F Stephen Hodi; Osama E Rahma Journal: Cancer Immunol Immunother Date: 2021-01-22 Impact factor: 6.968
Authors: Laurie E Steffen McLouth; Thomas W Lycan; Beverly J Levine; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Stefan C Grant; Nicholas M Pajewski; Kathryn E Weaver; W Jeffrey Petty Journal: Clin Lung Cancer Date: 2019-11-29 Impact factor: 4.785